SCHEMBL4043850

SCHEMBL4043850

O=C(O)c1cc2ccccc2c(=O)c2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
RXFP1 Q9HBX9 1/20 0.60
GPR35 Q9HC97 3/20 0.53
POLB P06746 1/20 0.53
HPGD P15428 3/20 0.52
ALDH1A1 P00352 2/20 0.52
KDM4E B2RXH2 2/20 0.52
HSD17B10 Q99714 2/20 0.52
NR4A1 P22736 1/20 0.52
NR4A2 P43354 1/20 0.52
NR4A3 Q92570 1/20 0.52
CYP1A2 P05177 1/20 0.52
GLA P06280 1/20 0.52
CYP2C19 P33261 1/20 0.52
AKR1B1 P15121 2/20 0.50
LMNA P02545 1/20 0.50
CYP2D6 P10635 1/20 0.50
GRIN2D O15399 1/20 0.49
GRIN2A Q12879 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL522958 0.86 MEN1 (0.71) MEN1KMT2ARXFP1GPR35POLB
SCHEMBL11881974 0.83 KDM4E (0.57) MEN1KMT2ARXFP1GPR35POLB
SCHEMBL28652 0.78 MEN1 (0.70) MEN1KMT2ARXFP1GPR35POLB
SCHEMBL30354048 0.78 MEN1 (0.70) MEN1KMT2ARXFP1GPR35POLB
SCHEMBL31401681 0.78 MEN1 (0.70) MEN1KMT2ARXFP1GPR35POLB
SCHEMBL18196201 0.77 MEN1 (0.56) MEN1KMT2ARXFP1GPR35POLB
SCHEMBL10417205 0.77 MEN1 (0.68) MEN1KMT2ARXFP1GPR35POLB
Cesium SCHEMBL31214843 0.77 MEN1 (0.68) MEN1KMT2ARXFP1GPR35POLB
Calcium SCHEMBL31214892 0.77 MEN1 (0.68) MEN1KMT2ARXFP1GPR35POLB
Magnesium SCHEMBL31214938 0.77 MEN1 (0.68) MEN1KMT2ARXFP1GPR35POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612054-B2 Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof NOVARTIS AG (CH) 2009-11-03 US disclosed
EP-1651592-B1 NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2009-04-29 EP disclosed
US-20070111991-A1 Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof NOVARTIS AG (CH) 2007-05-17 US disclosed
EP-1651592-A2 NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2006-05-03 EP disclosed
WO-2005014517-A2 NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111991-A1 Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof APP, BACE1, BCHE MEN1 2564/4885KMT2A 3287/4885RXFP1 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.